Echocardiography protocol for early detection of cardiac dysfunction in childhood cancer survivors in the multicenter DCCSS LATER 2 CARD study: Design, feasibility, and reproducibility

Merkx, Remy; Leerink, Jan M.; Feijen, E Lieke A M; Kremer, Leontien C. M.; Baat, Esmée C de; Bellersen, Louise; Dalen, Elvira C. van; Broeder, Eline van Dulmen‐den; Loo, Margriet van der Heiden‐van der; Heuvel‐Eibrink, Marry M. van den; Korte, Chris L. de; Loonen, Jacqueline; Louwerens, Marloes; Maas, Angela H.E.M.; Pinto, Yigal M.; Ronckers, Cécile M; Teske, Arco J.; Tissing, Wim J. E.; Vries, Andrica C H de; Mavinkurve‐Groothuis, Annelies M. C.; Pal, Helena J.H. van der; Weijers, Gert; Kok, Wouter E.; Kapusta, Livia

doi:10.1111/echo.15081

Cited by 12 publications

(14 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In ACMP cases and controls, echocardiographic parameters, including biplane LVEF, were measured by a core laboratory blinded for clinical characteristics. 14 In patients with DCM, echocardiographic parameters were obtained from medical records.…”

Section: Methodsmentioning

confidence: 99%

Candidate Plasma Biomarkers to Detect Anthracycline‐Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study

Leerink

Feijen

Moerland

et al. 2022

JAHA

Self Cite

View full text Add to dashboard Cite

Background Plasma biomarkers may aid in the detection of anthracycline‐related cardiomyopathy (ACMP). However, the currently available biomarkers have limited diagnostic value in long‐term childhood cancer survivors. This study sought to identify diagnostic plasma biomarkers for ACMP in childhood cancer survivors. Methods and Results We measured 275 plasma proteins in 28 ACMP cases with left ventricular ejection fraction <45%, 29 anthracycline‐treated controls with left ventricular ejection fraction ≥53% matched on sex, time after cancer, and anthracycline dose, and 29 patients with genetically determined dilated cardiomyopathy with left ventricular ejection fraction <45%. Multivariable linear regression was used to identify differentially expressed proteins. Elastic net model, including clinical characteristics, was used to assess discrimination of proteins diagnostic for ACMP. NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) and the inflammatory markers CCL19 (C‐C motif chemokine ligands 19) and CCL20, PSPD (pulmonary surfactant protein‐D), and PTN (pleiotrophin) were significantly upregulated in ACMP compared with controls. An elastic net model selected 45 proteins, including NT‐proBNP, CCL19, CCL20 and PSPD, but not PTN, that discriminated ACMP cases from controls with an area under the receiver operating characteristic curve (AUC) of 0.78. This model was not superior to a model including NT‐proBNP and clinical characteristics (AUC=0.75; P =0.766). However, when excluding 8 ACMP cases with heart failure, the full model was superior to that including only NT‐proBNP and clinical characteristics (AUC=0.75 versus AUC=0.50; P =0.022). The same 45 proteins also showed good discrimination between dilated cardiomyopathy and controls (AUC=0.89), underscoring their association with cardiomyopathy. Conclusions We identified 3 specific inflammatory proteins as candidate plasma biomarkers for ACMP in long‐term childhood cancer survivors and demonstrated protein overlap with dilated cardiomyopathy.

show abstract

Section: Methodsmentioning

confidence: 99%

Candidate Plasma Biomarkers to Detect Anthracycline‐Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study

Leerink

Feijen

Moerland

et al. 2022

JAHA

Self Cite

View full text Add to dashboard Cite

show abstract

“…A detailed echocardiography protocol was followed to ensure image quality and frame rate [14]. Two physicians (RM, JL) centrally performed standard structural and functional measurements, including biplane ejection fraction (LVEF) and diastolic function measurements [15,16].…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

“…Strain analyses were performed separately in vendor-independent software (2D CPA 1.4, TomTec Imaging Systems, Germany). End-systolic midwall global longitudinal strain (GLS) was calculated from three apical views [14,17,18]. GLS-rate represents the steepest slope of the GLS curve during systole.…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

“…Measurement feasibility was slightly lower in CCS than controls and generally in accordance with the literature. [14] Qualitative references regarding GLS and mid-GCS concern the absolute values (i.e. -18% is lower and worse than -20%).…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

“…Logistic regression analysis of abnormal LVEF may have been underpowered due to few events. Three-dimensional LVEF measurements were not systematically obtained in all participating centres and carried a high risk of selection bias [14]. Questionnaires were currently the best data source for medical history and medication use, since new diagnoses of heart failure, diabetes or hypertension at the current visit required referral, follow-up visits or additional investigations which were not recorded.…”

Section: Limitationsmentioning

confidence: 99%

See 2 more Smart Citations

Cardiac function in childhood cancer survivors treated with vincristine: Echocardiographic results from the DCCSS LATER 2 CARD study

Merkx¹,

Feijen²,

Leerink³

et al. 2022

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

Characteristics and research status among clinical trials in cardio‐oncology by bibliometric and visualized analysis

Lini,

Rong,

Wei

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Background We aim to establish the characteristics of published cardio‐oncology research of clinical trials by bibliometric analysis and to talk about the prospects and difficulties facing the development of cardio‐oncology. Methods Search of data related to clinical trials in cardiac oncology from 1990 to 2022 from the Web of Science core collection. Using CiteSpace to perform co‐citation analysis of authors, countries (regions) and institutions, journals and cited journals, cited authors and cited literature, and keywords. Results Of the 607 clinical trial studies, the number of papers published per year has increased over time. The regions with the greatest influence were North America (especially the United States) and Europe. Multicenter research has always been the focus of cardio‐oncology research, but cross‐regional cooperation was still lacking. Myocardial toxicity caused by anthracyclines has received the earliest attention and has been studied for the longest time. Meanwhile, the efficacy and cardiotoxicity of new anticancer drugs always came into focus, but at a slow pace. Few studies on myocardial toxicity were related to the treatment of tumors except breast cancer. Risk factors, heart disease, adverse outcomes, follow‐up, and intervention protection were the major hotspots revealed by co‐citation cluster. Conclusions There is great potential for the development of clinical trials in cardio‐oncology, especially in multicenter cooperation across different regions. Expansion of tumor types, myocardial toxicity of different drugs, and effective interventions in the research direction and design of clinical trials are necessary.

show abstract

Echocardiography protocol for early detection of cardiac dysfunction in childhood cancer survivors in the multicenter DCCSS LATER 2 CARD study: Design, feasibility, and reproducibility

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 12 publications

References 45 publications

Candidate Plasma Biomarkers to Detect Anthracycline‐Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study

Candidate Plasma Biomarkers to Detect Anthracycline‐Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study

Cardiac function in childhood cancer survivors treated with vincristine: Echocardiographic results from the DCCSS LATER 2 CARD study

Characteristics and research status among clinical trials in cardio‐oncology by bibliometric and visualized analysis

Contact Info

Product

Resources

About